Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Yuko Kitagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6469-2155; OpenAlex author ID A5011571209, A5113560688. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 3 papers

Papers 8

  1. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Co-author DOI 10.1158/1078-0432.ccr-25-2333↗
  2. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Last author DOI 10.1245/s10434-024-16851-z↗
  3. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Last author DOI 10.70352/scrj.cr.25-0076↗
  4. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Last author DOI 10.1002/cam4.7459↗
  5. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Last author DOI 10.1111/cas.16341↗
  6. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Last author DOI 10.1186/s12957-024-03609-w↗
  7. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma. Last author DOI 10.3892/ijo.2018.4662↗
  8. Evaluation of Suppressive Effects of Tranilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. Last author DOI 10.1097/mpa.0000000000000779↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 6 shared papers, 2024–2025 · strength 1.20
  2. Yuta Abe · 5 shared papers, 2024–2025 · strength 1.01
  3. Shutaro Hori · 4 shared papers, 2024–2025 · strength 0.83
  4. Masayuki Tanaka · 4 shared papers, 2024–2025 · strength 0.83
  5. Yutaka Nakano · 4 shared papers, 2024–2025 · strength 0.78
  6. Yohei Masugi · 3 shared papers, 2024–2025 · strength 0.65
  7. Gaku Shimane · 2 shared papers, 2024–2025 · strength 0.42
  8. Koichi Aiura · 2 shared papers, 2024 · strength 0.37
  9. Yutaka Endo · 2 shared papers, 2024 · strength 0.37
  10. Eisuke Iwasaki · 1 shared paper, 2025 · strength 0.23
  11. Hideaki Kojima · 1 shared paper, 2025 · strength 0.23
  12. Keiichi Suzuki · 2 shared papers, 2017–2019 · strength 0.21
  13. Hiroki Ozawa · 1 shared paper, 2025 · strength 0.19
  14. Zhou Luan · 1 shared paper, 2025 · strength 0.19
  15. Rosalie C. Sears · 1 shared paper, 2025 · strength 0.19
  16. Andrew J. Aguirre · 1 shared paper, 2025 · strength 0.19
  17. Donald W. Kufe · 1 shared paper, 2025 · strength 0.19
  18. Joseph Douglas Mancias · 1 shared paper, 2025 · strength 0.19
  19. Yutaka Takigawa · 1 shared paper, 2024 · strength 0.18
  20. Yasunori Sato · 1 shared paper, 2024 · strength 0.18
  21. Minoru Tanabe · 1 shared paper, 2024 · strength 0.18
  22. Sho Uemura · 1 shared paper, 2024 · strength 0.18
  23. Tatsuya Kawakami · 1 shared paper, 2024 · strength 0.18
  24. Junichi Matsui · 1 shared paper, 2024 · strength 0.18
  25. Yasuaki Kabe · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.